<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066868</url>
  </required_header>
  <id_info>
    <org_study_id>1020/2019</org_study_id>
    <nct_id>NCT04066868</nct_id>
  </id_info>
  <brief_title>Evaluating the Use of Patient-Reported Outcome Measures for Improving the Inter-Rater Reliability of Common Terminology Criteria for Adverse Event Ratings</brief_title>
  <official_title>Evaluating the Use of Patient-Reported Outcome Measures for Improving the Inter-Rater Reliability of Common Terminology Criteria for Adverse Event Ratings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bezirkskrankenhaus Kufstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università di Cagliari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansai Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King Hussein Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open randomized trial investigates, if clinicians complete CTCAE ratings differently&#xD;
      when receiving patients' patient-reported outcome (PRO) data prior to their CTCAE completion.&#xD;
      The primary objective is to demonstrate superior inter-rater reliability of CTCAE ratings&#xD;
      from physicians relying on EORTC PRO data as additional data source over traditional CTCAE&#xD;
      ratings not including PRO information.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In oncology, detection and tracking of adverse events (AEs) are a top priority in both&#xD;
      clinical trials and routine care. The classification of AEs mostly relies on the Common&#xD;
      Toxicity Terminology for Adverse Events (CTCAE) developed by the US-American National&#xD;
      Institutes of Health and the National Cancer Institute.&#xD;
&#xD;
      It is known, however, that the assessment of AEs can greatly vary depending on whether they&#xD;
      are assessed by patients or by clinicians.&#xD;
&#xD;
      Procedure: The patients (any oncological diagnosis, day clinic or inpatient for treatment&#xD;
      with chemotherapy or immunotherapy; open 1:1 randomized) fill out an EORTC quality of life&#xD;
      questionnaire electronically (C30 + further questions). These PRO data are immediately&#xD;
      available for the clinicians. Independently of each other, two different clinicians conduct a&#xD;
      medical consultation with the patient and electronically a CTCAE rating. For the intervention&#xD;
      Group, clinicians see the PRO values directly next to the input options for the CTCAE rating.&#xD;
      For the control Group, clinicians see the input options for the CTCAE rating. The similarity&#xD;
      of the assessments is checked using intra-class correlation.&#xD;
&#xD;
      The combined use of PROs and CTCAE data makes particular sense for AEs/aspects that are&#xD;
      directly experienced by the patient (fatigue, pain, cognitive problems, emotional&#xD;
      functioning, ...) and can only be adequately recorded by the clinician through communication&#xD;
      with the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC Quality of Life Questionnaire C30 and additional questions from the EORTC Item Library</measure>
    <time_frame>single assessment of quality of life before the medical consultation</time_frame>
    <description>patient-reported quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTCAE V4.0</measure>
    <time_frame>single assessment during the medical consultation with physician 1 on the same day of PRO assessment</time_frame>
    <description>physician 1 rates patient symptoms (17 CTCAE domains matching the EORTC C30 and additional questions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTCAE V4.0</measure>
    <time_frame>single assessment during the medical consultation with physician 2 on the same day of PRO assessment</time_frame>
    <description>physician 2 rates patient symptoms (17 CTCAE domains matching the EORTC C30 and additional questions)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1024</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>PRO active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO not active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient-reported outcomes assessment</intervention_name>
    <description>Patient-reported outcomes are electronically assessed using EORTC QOL measures</description>
    <arm_group_label>PRO active</arm_group_label>
    <arm_group_label>PRO not active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CTCAE rating</intervention_name>
    <description>CTCAE Ratings are conducted by clinicians</description>
    <arm_group_label>PRO active</arm_group_label>
    <arm_group_label>PRO not active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRO data is displayed</intervention_name>
    <description>PRO data is displayed right next to the CTCAE rating</description>
    <arm_group_label>PRO active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any Cancer diagnosis&#xD;
&#xD;
          -  current treatment with chemotherapy or immunotherapy&#xD;
&#xD;
          -  symptom burden equal or greater score 3 of the screening question &quot;On a scale of 0 to&#xD;
             10, to what degree did you experience physical or emotional symptoms/problems during&#xD;
             the last week?&quot;&#xD;
&#xD;
          -  ability to understand the questions linguistically and cognitively&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criterion:&#xD;
&#xD;
          -  psychiatric diagnosis or mental health problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernhard Holzner, Prof. PhD</last_name>
    <phone>+43(0)50 504 24253</phone>
    <email>berhard.holzner@tirol-kliniken.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Kufstein</name>
      <address>
        <city>Kufstein</city>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>August Zabernigg, MD</last_name>
      <email>interne@bkh-kufstein.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patient-reported outcomes (PRO)</keyword>
  <keyword>common terminology criteria for adverse events (CTCAE)</keyword>
  <keyword>quality of life</keyword>
  <keyword>electronic data assessment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

